Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca    AZN   GB0009895292

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
The feature you requested does not exist. However, we suggest the following feature:

AstraZeneca : reaches another milestone with Imfinzi trial

share with twitter share with LinkedIn share with facebook
share via e-mail
05/26/2018 | 10:39am CEST

AstraZeneca, along with its biologics research and development arm MedImmune, announced positive overall survival results for the Phase III PACIFIC trial on Friday.

The FTSE 100 drugmaker described PACIFIC as a randomised, double-blinded, placebo-controlled, multi-centre trial of Imfinzi (durvalumab) in patients with unresectable Stage III non-small cell lung cancer (NSCLC), whose disease had not progressed following platinum-based chemotherapy concurrent with radiation therapy (CRT).

It said a planned interim analysis conducted by an independent data monitoring committee concluded that the trial has met its second of two primary endpoints by showing statistically-significant overall survival benefit with clinically-meaningful improvement in patients receiving Imfinzi compared to placebo.

The safety and tolerability profile for Imfinzi was said to be consistent with that reported at the time of the progression-free survival analysis.

AstraZeneca planned to present results from the PACIFIC trial at a forthcoming medical meeting.

The readout of positive overall survival data at the interim analysis of the PACIFIC trial provides additional compelling evidence of the clinical benefit that Imfinzi can offer patients in this earlier stage of lung cancer, said AstraZenecas chief medical officer Sean Bohen.

We look forward to sharing these results with health authorities to support ongoing regulatory interactions and to update the Imfinzi label with these important data.

In May last year, AstraZeneca announced that the PACIFIC trial met its first primary endpoint of progression-free survival by demonstrating a median improvement of 11.2 months compared to placebo, as assessed by blinded independent central review.

Imfinzi is currently approved in the US and Canada for the treatment of patients with unresectable Stage III NSCLC who had not progressed following platinum-based chemoradiation therapy.

It was currently under regulatory review in the EU, Japan and other jurisdictions with expected decisions in the second half of 2018.

(c) 2003-2018 SudanTribune - All rights reserved. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ASTRAZENECA
10:39aASTRAZENECA : reaches another milestone with Imfinzi trial
10:22aASTRAZENECA : Success for AstraZeneca after lung cancer treatment improves survi..
10:21aASTRAZENECA : expands alliance with Bicycle Therapeutics
05/25ASTRAZENECA : Study Data from AstraZeneca Provide New Insights into Breast Cance..
05/25ASTRAZENECA : Investigators at AstraZeneca Describe Findings in Catheterization ..
05/25ASTRAZENECA : Emulate, Inc. and AstraZeneca Form Strategic Agreement to Work Sid..
05/25ASTRAZENECA : Researchers from AstraZeneca Provide Details of New Studies and Fi..
05/25ASTRAZENECA : Reports on Antidiabetic Agents from AstraZeneca Provide New Insigh..
05/25INVESTIGATORS AT ASTRAZENECA ZERO IN : Is it the Dawn of a New Beginning?)
05/25ASTRAZENECA : IMFINZI® (Durvalumab) Significantly Improves Overall Survival in t..
More news
News from SeekingAlpha
05/25WALL STREET BREAKFAST, MAY 25TH : EU Data Privacy Rules Take Effect; U.S. And Ch.. 
05/25AstraZeneca's Imfinzi successful in late-state lung cancer study 
05/25WALL STREET BREAKFAST : New Privacy Bar With GDPR 
05/25Healthcare roundup 
05/24Merck Appears Unstoppable In Treating Front-Line Lung Cancer 
Financials ($)
Sales 2018 22 463 M
EBIT 2018 5 422 M
Net income 2018 1 899 M
Debt 2018 14 637 M
Yield 2018 3,77%
P/E ratio 2018 39,02
P/E ratio 2019 30,84
EV / Sales 2018 4,78x
EV / Sales 2019 4,50x
Capitalization 92 832 M
Duration : Period :
AstraZeneca Technical Analysis Chart | AZN | GB0009895292 | 4-Traders
Technical analysis trends ASTRAZENECA
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 31
Average target price 74,4 $
Spread / Average Target 2,1%
EPS Revisions
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Dunoyer Chief Financial Officer & Executive Director
Sean Bohen Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA5.99%92 832
JOHNSON & JOHNSON-11.45%325 801
PFIZER-0.91%208 713
NOVARTIS-8.30%194 397
ROCHE HOLDING LTD.-9.17%189 708